These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 20803547)
1. Glypican 3 binds to GLUT1 and decreases glucose transport activity in hepatocellular carcinoma cells. Cho HS; Ahn JM; Han HJ; Cho JY J Cell Biochem; 2010 Dec; 111(5):1252-9. PubMed ID: 20803547 [TBL] [Abstract][Full Text] [Related]
2. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Capurro MI; Xiang YY; Lobe C; Filmus J Cancer Res; 2005 Jul; 65(14):6245-54. PubMed ID: 16024626 [TBL] [Abstract][Full Text] [Related]
3. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870 [TBL] [Abstract][Full Text] [Related]
4. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Kandil DH; Cooper K Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373 [TBL] [Abstract][Full Text] [Related]
5. Identification of Glypican3 as a novel GLUT4-binding protein. Taguchi A; Emoto M; Okuya S; Fukuda N; Nakamori Y; Miyazaki M; Miyamoto S; Tanabe K; Aburatani H; Oka Y; Tanizawa Y Biochem Biophys Res Commun; 2008 May; 369(4):1204-8. PubMed ID: 18343214 [TBL] [Abstract][Full Text] [Related]
6. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. Capurro M; Martin T; Shi W; Filmus J J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449 [TBL] [Abstract][Full Text] [Related]
7. The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Davoodi J; Kelly J; Gendron NH; MacKenzie AE Proteomics; 2007 Jun; 7(13):2300-10. PubMed ID: 17549790 [TBL] [Abstract][Full Text] [Related]
8. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. Filmus J; Capurro M FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321 [TBL] [Abstract][Full Text] [Related]
9. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging. Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086 [TBL] [Abstract][Full Text] [Related]
10. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368 [TBL] [Abstract][Full Text] [Related]
11. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560 [TBL] [Abstract][Full Text] [Related]
12. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914 [TBL] [Abstract][Full Text] [Related]
13. Role of Glycanation and Convertase Maturation of Soluble Glypican-3 in Inhibiting Proliferation of Hepatocellular Carcinoma Cells. Saad A; Liet B; Joucla G; Santarelli X; Charpentier J; Claverol S; Grosset CF; Trézéguet V Biochemistry; 2018 Feb; 57(7):1201-1211. PubMed ID: 29345911 [TBL] [Abstract][Full Text] [Related]
14. Interaction of glucose transporter 1 with anion exchanger 1 in vitro. Jiang W; Ding Y; Su Y; Jiang M; Hu X; Zhang Z Biochem Biophys Res Commun; 2006 Jan; 339(4):1255-61. PubMed ID: 16343432 [TBL] [Abstract][Full Text] [Related]
15. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells. Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957 [TBL] [Abstract][Full Text] [Related]
16. Organic anion transport in HepG2 cells: absence of the high-affinity, chloride-dependent transporter. Min AD; Goeser T; Liu R; Campbell CG; Novikoff PM; Wolkoff AW Hepatology; 1991 Dec; 14(6):1217-23. PubMed ID: 1660021 [TBL] [Abstract][Full Text] [Related]
17. Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling. Sung YK; Hwang SY; Farooq M; Kim JC; Kim MK Exp Mol Med; 2003 Aug; 35(4):257-62. PubMed ID: 14508064 [TBL] [Abstract][Full Text] [Related]
18. Properties of the human erythrocyte glucose transport protein are determined by cellular context. Levine KB; Robichaud TK; Hamill S; Sultzman LA; Carruthers A Biochemistry; 2005 Apr; 44(15):5606-16. PubMed ID: 15823019 [TBL] [Abstract][Full Text] [Related]
19. Dual action of phenylarsine oxide on the glucose transport activity of GLUT1. Scott J; Opejin A; Tidball A; Stehouwer N; Rekman J; Louters LL Chem Biol Interact; 2009 Dec; 182(2-3):199-203. PubMed ID: 19686715 [TBL] [Abstract][Full Text] [Related]
20. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]